Description
An HDAC6 inhibitor (IC50 = 2.6 nM); selective for HDAC6 over HDAC1-3, HDAC7, and HDAC9 (IC50s = 35, 45, 46, 7,300, and 137 nM, respectively), as well as HDAC4, HDAC5, and HDAC9 (IC50 = >20,000 nM for all); reduces proliferation of A2780, TOV-21G, and MDA-MB-231 cells at 3 µM and completely inhibits it and induces apoptosis at 10 µM; inhibits proliferation in MiaPaCa-2, TOV-21G, and T47D cells when used in combination with paclitaxel; reduces tumor growth in a MiaPaCa-2 mouse xenograft model at 50 mg/kg when used in combination with paclitaxel; reduces hepatorenal cystogenesis in a rat model of polycystic liver disease when used in combination with pasireotide
Formal name: 2-[(2-chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide
Synonyms: Citarinostat
Molecular weight: 468
CAS: 1316215-12-9
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors|Deacetylases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Epigenetics, Transcription, & Translation|Erasers|Histone Deacetylation
